Like their older counterparts, the newer anticonvulsants gabapentin, lamotrigine, and topiramate show promise for treating various off-label psychiatric and neurologic disorders. This review examines the quality of current evidence for these new uses, identifies where gaps in the evidence lie, and discusses which emerging uses of individual agents appear most justified.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Emerging uses of the new anticonvulsants: What's the state of the evidence? (PDF)

Newsletter